Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Recap: Avanos Medical Q1 Earnings
Avanos Medical (NYSE:AVNS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Avanos Medical reported in-line EPS of $0.26 versus an estimate of $0.26.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Avanos Medical’s Earnings Outlook
Avanos Medical (NYSE:AVNS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that Avanos Medical will report an earnings per share (EPS) of $0.26.
Avanos Medical Earlier Reported Q4 EPS $0.46 Beats $0.40 Estimate, Sales $193.40M Beat $191.32M Estimate
Avanos Medical (NYSE:AVNS) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.40 by 15 percent. This is a 64.29 percent increase over earnings of $0.28 per share from the same
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
Avanos Medical Earnings Preview
Avanos Medical (NYSE:AVNS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement.
Analysts estimate that Avanos Medical will report an earnings per share (EPS) of $0.40.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna’s Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours.